Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effects of Dopaminergic Therapy in Patients With Alzheimer's Disease: a Phase II 24-week, Randomized, Double-blind Placebo Controlled Study.

NCT03250741 is registered in ClinicalTrials.gov with I.R.C.C.S. Fondazione Santa Lucia as lead sponsor.

NCT NCT03250741
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03250741 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effects of Dopaminergic Therapy in Patients With Alzheimer's Disease: a Phase II 24-week, Randomized, Double-blind Placebo Controlled Study.
Lead sponsor
I.R.C.C.S. Fondazione Santa Lucia
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2016
Completion date
November 30, 2018
Enrollment
94 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer disease